Stock listing
Lang & Schwarz:A140E0 Regenxbio Inc. Aktie
German listing (Lang & Schwarz) of Regenxbio Inc. · home listing NASDAQ:RGNX
Follow Regenxbio Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RGNX
$7.16 USD -0.10 (-1.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RGNX
- Day range
- $6.86 – $7.30 USDNov 20, 2026
- Volume
- 1.05M sharesNov 20, 2026
- Market cap
- $473.4M USDAt the close on Nov 20, 2026 · price × 66.12M shares outstanding
- 52-week range
- $5.46 – $16.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.96M USDMedian day 1.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RGNX · Home | $7.16 USD | -0.10 (-1.4%) | 1,054,138 | $7.00 | $7.30 | $6.86 | $7.26 | Close on Nov 20, 2026 |
| Frankfurt:RB0 | €6.412 EUR | -0.23 (-3.5%) | — | €6.412 | €6.412 | €6.412 | €6.642 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RGNX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.16 | -0.10 | -1.4% | $7.00 | $7.30 | $6.86 | 1,054,138 | |
| $7.26 | +0.02 | +0.3% | $7.23 | $7.56 | $7.12 | 700,292 | |
| $7.24 | -0.08 | -1.1% | $7.35 | $7.493 | $6.84 | 963,087 | |
| $7.32 | -0.32 | -4.2% | $7.59 | $7.815 | $7.30 | 908,089 | |
| $7.64 | -0.39 | -4.9% | $8.02 | $8.02 | $7.39 | 716,119 | |
| $8.03 | -0.44 | -5.2% | $8.23 | $8.33 | $7.94 | 1,283,919 | |
| $8.47 | +0.78 | +10.1% | $7.62 | $8.88 | $7.62 | 1,845,043 | |
| $7.69 | -0.38 | -4.7% | $8.06 | $8.14 | $7.28 | 1,084,412 | |
| $8.07 | +0.45 | +5.9% | $7.77 | $8.23 | $7.47 | 2,173,999 | |
| $7.62 | +0.24 | +3.3% | $7.33 | $7.87 | $7.33 | 1,186,481 | |
| $7.38 | -0.33 | -4.3% | $7.20 | $7.68 | $7.15 | 1,677,167 | |
| $7.71 | +0.08 | +1.0% | $7.72 | $7.96 | $7.475 | 1,135,429 | |
| $7.63 | +0.47 | +6.6% | $7.29 | $7.645 | $7.266 | 854,953 | |
| $7.16 | -0.04 | -0.6% | $7.27 | $7.459 | $7.04 | 1,029,332 | |
| $7.20 | -0.21 | -2.8% | $7.38 | $7.535 | $7.00 | 1,061,611 | |
| $7.41 | +0.17 | +2.3% | $7.36 | $7.625 | $7.21 | 1,033,352 | |
| $7.24 | +0.64 | +9.7% | $6.52 | $7.285 | $6.505 | 1,998,860 | |
| $6.60 | +0.02 | +0.3% | $6.54 | $6.78 | $6.459 | 1,219,377 | |
| $6.58 | -0.10 | -1.5% | $6.83 | $6.89 | $6.485 | 1,137,663 | |
| $6.68 | -0.49 | -6.8% | $7.03 | $7.08 | $6.628 | 1,441,500 | |
| $7.17 | 0.00 | 0.0% | $7.11 | $7.305 | $6.98 | 1,132,500 | |
| $7.17 | -0.23 | -3.1% | $7.42 | $7.47 | $7.15 | 945,300 | |
| $7.40 | +0.25 | +3.5% | $7.15 | $7.58 | $7.06 | 1,315,100 | |
| $7.15 | +0.225 | +3.2% | $6.98 | $7.265 | $6.95 | 1,298,000 | |
| $6.925 | -0.235 | -3.3% | $7.14 | $7.18 | $6.875 | 1,210,200 | |
| $7.16 | +0.28 | +4.1% | $6.88 | $7.28 | $6.83 | 1,228,300 | |
| $6.88 | -0.38 | -5.2% | $7.12 | $7.24 | $6.80 | 1,564,900 | |
| $7.26 | -0.51 | -6.6% | $7.66 | $7.72 | $7.11 | 1,378,400 | |
| $7.77 | -0.30 | -3.7% | $8.12 | $8.29 | $7.74 | 2,033,600 | |
| $8.07 | -0.02 | -0.2% | $8.03 | $8.275 | $7.95 | 859,100 | |
| $8.09 | +0.495 | +6.5% | $7.50 | $8.31 | $7.44 | 2,258,800 | |
| $7.595 | +0.145 | +1.9% | $7.31 | $7.73 | $7.20 | 1,004,900 | |
| $7.45 | -0.31 | -4.0% | $7.79 | $7.84 | $7.33 | 1,164,100 | |
| $7.76 | +0.33 | +4.4% | $7.80 | $8.16 | $7.57 | 2,349,800 | |
| $7.43 | +0.01 | +0.1% | $7.58 | $7.62 | $7.36 | 1,036,600 | |
| $7.42 | -0.11 | -1.5% | $7.52 | $7.736 | $7.30 | 1,705,100 | |
| $7.53 | +0.08 | +1.1% | $7.49 | $7.86 | $7.35 | 1,788,600 | |
| $7.45 | -0.02 | -0.3% | $7.41 | $7.64 | $7.33 | 2,095,900 | |
| $7.47 | +0.07 | +0.9% | $7.30 | $7.495 | $7.17 | 1,325,800 | |
| $7.40 | +0.16 | +2.2% | $7.53 | $7.675 | $7.165 | 1,276,500 | |
| $7.24 | -0.26 | -3.5% | $7.45 | $7.46 | $7.12 | 1,509,200 | |
| $7.50 | -0.65 | -8.0% | $8.13 | $8.145 | $7.40 | 1,112,900 | |
| $8.15 | +0.27 | +3.4% | $8.03 | $8.25 | $7.904 | 1,202,500 | |
| $7.88 | -0.15 | -1.9% | $8.24 | $8.313 | $7.76 | 1,115,700 | |
| $8.03 | -0.185 | -2.3% | $8.22 | $8.331 | $8.00 | 3,374,800 | |
| $8.215 | +0.235 | +2.9% | $8.34 | $8.56 | $8.02 | 1,808,100 | |
| $7.98 | +0.035 | +0.4% | $7.93 | $7.99 | $7.636 | 1,231,600 | |
| $7.945 | -0.745 | -8.6% | $8.69 | $8.75 | $7.78 | 1,426,600 | |
| $8.69 | +0.16 | +1.9% | $8.58 | $8.728 | $8.49 | 858,400 | |
| $8.53 | -0.03 | -0.4% | $8.69 | $8.82 | $8.39 | 1,029,100 | |
| $8.56 | -0.17 | -1.9% | $8.63 | $8.79 | $8.47 | 1,172,100 | |
| $8.73 | -0.03 | -0.3% | $8.70 | $9.025 | $8.62 | 1,407,400 | |
| $8.76 | -0.18 | -2.0% | $8.95 | $8.95 | $8.60 | 998,700 | |
| $8.94 | -0.26 | -2.8% | $9.09 | $9.215 | $8.86 | 1,069,100 | |
| $9.20 | -0.40 | -4.2% | $9.56 | $9.56 | $9.00 | 839,200 | |
| $9.60 | +0.28 | +3.0% | $9.34 | $9.708 | $9.20 | 866,300 | |
| $9.32 | -0.18 | -1.9% | $9.38 | $9.616 | $9.28 | 783,700 | |
| $9.50 | -0.16 | -1.7% | $9.50 | $9.68 | $9.09 | 1,611,400 | |
| $9.66 | +0.29 | +3.1% | $10.00 | $10.10 | $9.212 | 1,752,500 | |
| $9.37 | -0.01 | -0.1% | $9.35 | $9.46 | $9.04 | 916,600 | |
| $9.38 | +0.47 | +5.3% | $8.85 | $9.43 | $8.61 | 1,160,000 | |
| $8.91 | +0.855 | +10.6% | $8.14 | $8.99 | $8.13 | 1,756,781 | |
| $8.055 | -2.665 | -24.9% | $8.29 | $8.64 | $7.77 | 5,446,547 | |
| $10.72 | -0.34 | -3.1% | $11.14 | $11.16 | $10.49 | 1,005,500 | |
| $11.06 | -0.96 | -8.0% | $11.98 | $12.08 | $11.03 | 947,300 |
- Ticker
- Lang & Schwarz:A140E0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
Latest earnings call · Nov 5, 2026
REGENXBIO (NASDAQ:RGNX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 40 slides
Latest news
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
Nov 5, 2026
Closed $7.38 (-4.3%) on Nov 5, 2026
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
Nov 3, 2026
Closed $7.63 (+6.6%) on Nov 3, 2026
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
Oct 29, 2026
Closed $7.41 (+2.3%) on Oct 29, 2026
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Oct 12, 2026
Closed $7.77 (-3.7%) on Oct 12, 2026
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Sep 24, 2026
Closed $7.40 (+2.2%) on Sep 25, 2026
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
Aug 25, 2026
Closed $8.91 (+10.6%) on Aug 25, 2026
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
Aug 24, 2026
Closed $8.06 (-24.9%) on Aug 24, 2026
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Aug 6, 2026
Closed $11.28 (+7.4%) on Aug 6, 2026
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
Aug 3, 2026
Closed $9.96 (+2.8%) on Aug 3, 2026
Regenxbio Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 223 in all · newest Nov 5, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 5, 2026
- Decks
- 22 decks · latest September 2026
Where Regenxbio Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RGNX · Home listing | NASDAQ | United States | USD |
| gettex:RB0 | gettex | Germany | EUR |
| LS Exchange:A140E0 | LS Exchange | Germany | EUR |
| Tradegate:RB0 | Tradegate | Germany | EUR |
| Lang & Schwarz:A140E0 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:RB0 | Frankfurt | Germany | EUR |
| BOATS:RGNX | BOATS | United States | USD |
| Munich:RB0 | Munich | Germany | EUR |
| Dusseldorf:RB0 | Dusseldorf | Germany | EUR |
| Stuttgart:RB0 | Stuttgart | Germany | EUR |
Valuation
EV/sales 1.9× against a median of 13.1×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $289.0M USD
- P/E
- Loss
- EV/sales
- 1.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.2×
- Gross margin
- 87.5%
- Operating margin
- −95.7%
- Net margin
- −113.9%
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 1.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$496.9M | US$470.4M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| Median of the others | US$472.0M | US$311.6M | 13.1× | 2.3× | −200.8% | 0.0× | 1.14 |
Forecasts
7 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.77 · 2 analysts
- Revenue, year to Dec 2026
- 153.8M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Curran M. Simpson | President and Chief Executive Officer, Board Member |
| Mitchell Chan | CHIEF FINANCIAL OFFICER |
| Patrick J. Christmas | CHIEF LEGAL OFFICER |
| Dana Cormack | Corporate Communications |
| Craig Malzahn | Chief Technology Officer |
| Marianne Kreiner | Head of People |
| Olivier Danos | CHIEF SCIENTIFIC OFFICER |
| Ram Palanki | Chief Commercial Officer |
| Steve Pakola | CHIEF MEDICAL OFFICER |
Board
| Director | Role |
|---|---|
| George Migausky | Chairman of the Board |
| Alexandra Glucksmann | Independent Board Member |
| Allan Fox | Independent Board Member |
| Curran M. Simpson | President and Chief Executive Officer, Board Member |
| Daniel Tassé | Independent Board Member |
| David Stump | Independent Board Member |
| Greg Ciongoli | Independent Board Member |
| Jennifer Zachary | Independent Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| REGENXBIO (NASDAQ:RGNX) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q1 2026 Earnings Call | Thu, May 14, 2026 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q1 2025 Earnings Call | Mon, May 12, 2025 · 4:30 PM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q4 2024 Earnings Call | Thu, Mar 13, 2025 · 4:30 PM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| REGENXBIO (NASDAQ:RGNX) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −4.3% |
| Q2 2026 | Aug 6, 2026 · Before open | +7.4% |
| Q1 2026 | May 14, 2026 · Before open | −37.8% |
| Q4 2025 | Mar 5, 2026 | −5.4% |
| Q3 2025 | Nov 6, 2025 · Before open | −3.8% |
| Q2 2025 | Aug 7, 2025 · Before open | −4.0% |
| Q1 2025 | May 12, 2025 · After close | +2.6% |
| Q4 2024 | Feb 25, 2025 · Before open | −3.0% |
| Q3 2024 | Nov 6, 2024 · After close | +18.7% |
| Q2 2024 | Aug 1, 2024 · After close | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −5.9% |
| Q4 2023 | Feb 27, 2024 · After close | −0.6% |
| Q3 2023 | Nov 8, 2023 · After close | +2.4% |
| Q2 2023 | Aug 2, 2023 · After close | −7.5% |
| Q1 2023 | May 3, 2023 · After close | −1.6% |
| Q4 2022 | Feb 28, 2023 · After close | +8.5% |
| Q3 2022 | Nov 3, 2022 · Before open | −13.2% |
| Q2 2022 | Aug 3, 2022 · After close | +2.2% |
| Q1 2022 | May 4, 2022 · After close | −14.9% |
| Q4 2021 | Mar 1, 2022 · After close | +10.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 40 slides | September 2026 |
| American Society of Retina Specialists (ASRS) 2026 | Conference | 10 slides | July 2026 |
| Q4 2025 Earnings Presentation | Earnings | 23 slides | Mar 5, 2026 |
| AAO 2025 | Conference | 23 slides | Oct 17, 2025 |
| World Muscle Society Annual Congress 2025 | Conference | 7 slides | October 2025 |
| ICIEM 2025 | Conference | 17 slides | Sep 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 13 slides | Aug 7, 2025 |
| AAN 2025 | Conference | 12 slides | 2025 |
| Technical Presentation (October 2024) | Technical | 17 slides | Oct 19, 2024 |
| ASGCT 2024 | Conference | 12 slides | May 11, 2024 |
All 22 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SSIEM 2023 | Conference | 16 slides | Aug 30, 2023 |
| SSIEM 2023 | Conference | 14 slides | Aug 30, 2023 |
| ASRS 2023 | Conference | 13 slides | Jul 30, 2023 |
| WORLDSymposium 2023 | Conference | 15 slides | March 2023 |
| WORLDSymposium 2023 | Conference | 14 slides | Feb 24, 2023 |
| Technical Presentation (October 2022) | Technical | 19 slides | Oct 3, 2022 |
| AAO 2022 | Conference | 16 slides | 2022 |
| WORLDSymposium 2021 | Conference | 17 slides | Feb 11, 2021 |
| AAO Retina Subspecialty Days 2019 | Conference | 24 slides | Oct 15, 2019 |
| Technical Presentation (October 2018) | Technical | 18 slides | Oct 29, 2018 |
| Q2 2018 Earnings Presentation | Earnings | 26 slides | Aug 8, 2018 |
| Investor Presentation (September 2016) | Investor deck | 29 slides | Sep 12, 2016 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$108M raised · US$9 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Mizuho (co-lead) Use of proceeds: Extend cash runway into Q4 2027 and support the planned AFFINITY RISE ex-U.S. randomized-controlled trial of RGX-202 in 1H 2027 | Aug 6, 2026 |
| Limited recourse royalty bond with warrants Tranche closed: US$150M raised · Warrants at US$14.92 Buyers: Healthcare Royalty (HCRx) (up to $250 million bond; $150 million funded at closing, plus warrants for up to 268,096 shares) Use of proceeds: Extend cash runway into early 2027 and fund late-stage activities and commercial preparations | May 19, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$22.00 a share on Sep 16, 2015.
- Price
- US$22.00 a share
- Shares offered
- 6,300,000 shares of common stock
- Offering size
- US$138.6 million
- Underwriters' option
- Up to 945,000 more shares
- Underwriters
- MORGAN STANLEY, BofA MERRILL LYNCH, PIPER JAFFRAY, CHARDAN CAPITAL MARKETS, LLC · In the order on the cover
- Shares delivered
- On or about Sep 22, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 1, 2015 |
| Filed publicly | Aug 17, 2015 |
| Amended 3 times | Newest Sep 16, 2015 |
| Shares registered with an exchange | Sep 9, 2015 |
| Declared effective by the SEC | Sep 16, 2015 |
| Final prospectus, with the price | Sep 17, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 17, 2015 |
| EFFECT · Notice that a registration is effective | Sep 16, 2015 |
| S-1MEF · Registration of more shares for the same offering | Sep 16, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Sep 16, 2015 |
| S-1/A · Registration statement, amended | Sep 16, 2015 |
| S-1/A · Registration statement, amended | Sep 15, 2015 |
| CORRESP · Letter to the SEC | Sep 14, 2015 |
| CORRESP · Letter to the SEC | Sep 14, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 9, 2015 |
| S-1/A · Registration statement, amended | Sep 8, 2015 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 28, 2015 |
| CORRESP · Letter to the SEC | Aug 27, 2015 |
| UPLOAD · Letter from the SEC | Aug 26, 2015 |
| S-1 · Registration statement | Aug 17, 2015 |
| DRSLTR · Letter to the SEC with a draft | Aug 10, 2015 |
| DRS/A · Draft registration statement, amended | Aug 10, 2015 |
| UPLOAD · Letter from the SEC | Jul 28, 2015 |
| DRS · Draft registration statement | Jul 1, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 170.4M | 83.3M | 90.2M | 112.7M | 470.3M | 154.6M | 35.2M | 218.5M | 10.4M | 4.59M |
| Cost of revenue | 20.3M | 33.6M | 37.2M | 54.5M | 51.8M | 35.7M | 8.24M | 9.64M | 1.71M | 98.0K |
| Gross profit | 150.1M | 49.8M | 53.0M | 58.2M | 418.5M | 118.9M | 27.0M | 208.9M | 8.68M | 3.63M |
| Research and development | 228.3M | 208.5M | 232.3M | 242.5M | 181.4M | 166.3M | 124.2M | 83.9M | 57.2M | 45.5M |
| Selling, general and administrative | 82.9M | 76.6M | 88.5M | 85.3M | 79.3M | 63.8M | 51.8M | 36.9M | 27.2M | 23.6M |
| Operating income | -161.2M | -233.3M | -268.1M | -262.9M | 160.0M | -119.2M | -149.0M | 88.1M | -75.9M | -65.3M |
| Depreciation and amortization | 15.6M | 16.2M | 17.3M | 12.9M | 9.56M | 8.41M | 7.15M | 3.98M | 2.69M | 544.0K |
| EBITDA | -145.6M | -217.1M | -250.8M | -250.0M | 169.5M | -110.8M | -141.8M | 92.1M | -73.2M | -64.8M |
| Interest expense | 45.0M | 12.7M | 6.86M | 23.3M | 26.3M | 771.0K | 107.2M | 0 | 0 | 0 |
| Income before tax | -193.9M | -227.1M | -263.6M | -280.4M | 141.2M | -106.0M | -97.5M | 104.1M | -73.2M | -63.4M |
| Income tax | 0 | 0 | -152.0K | -84.0K | 13.4M | 5.24M | -2.75M | 4.18M | 0 | -435.0K |
| Net income | -193.9M | -227.1M | -263.5M | -280.3M | 127.8M | -111.3M | -94.7M | 99.9M | -73.2M | -63.0M |
| Earnings per share, basic | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.99 | -2.45 | -2.38 |
| Earnings per share, diluted | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 34.5M | 57.5M | 34.5M | 97.0M | 345.2M | 338.4M | 69.5M | 75.6M | 46.7M | 24.8M |
| Short-term investments | 195.6M | 177.2M | 240.7M | 267.7M | 112.2M | 137.3M | 226.7M | 244.2M | 114.1M | 64.7M |
| Receivables | 26.4M | 20.5M | 24.8M | 28.1M | 32.4M | 43.0M | 38.1M | 8.59M | 473.0K | 1.03M |
| Inventory | 13.9M | 18.8M | 10.5M | 6.47M | 5.73M | 5.33M | 1.77M | |||
| Current assets | 281.3M | 278.0M | 335.0M | 416.0M | 518.8M | 531.2M | 345.0M | 337.9M | 168.0M | 93.4M |
| Property, plant and equipment | 104.9M | 117.6M | 132.1M | 141.7M | 131.5M | 56.5M | 29.0M | 28.7M | 14.0M | 9.32M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 453.0M | 466.0M | 574.0M | 833.3M | 1.11B | 708.2M | 497.9M | 543.8M | 198.7M | 172.7M |
| Accounts payable | 21.4M | 22.8M | 22.8M | 27.2M | 11.4M | 10.6M | 6.41M | 4.41M | 4.83M | 1.54M |
| Current liabilities | 118.1M | 103.2M | 130.3M | 130.4M | 130.5M | 81.4M | 33.7M | 22.2M | 14.4M | 9.67M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 260.5M | 82.0M | 89.3M | 94.8M | 86.7M | 72.7M | 11.3M | 5.85M | ||
| Total liabilities | 350.3M | 206.3M | 262.2M | 317.1M | 349.6M | 330.4M | 47.7M | 35.0M | 15.6M | 11.0M |
| Shareholders' equity | 102.7M | 259.7M | 311.7M | 516.2M | 764.3M | 377.8M | 450.2M | 508.8M | 183.0M | 161.7M |
| Shares outstanding | 50.9M | 49.5M | 44.0M | 43.3M | 42.8M | 37.5M | 37.0M | 36.1M | 31.3M | 26.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -124.0M | -173.1M | -218.4M | -207.5M | 218.9M | -54.1M | -107.7M | 104.6M | -58.0M | -48.6M |
| Capital spending | -2.41M | -2.44M | -9.96M | -30.7M | -84.2M | -26.9M | -11.7M | -13.3M | -7.16M | -8.15M |
| Free cash flow | -126.4M | -175.6M | -228.4M | -238.2M | 134.7M | -80.9M | -119.4M | 91.4M | -65.2M | -56.7M |
| Cash from investing | -15.9M | 103.4M | 190.9M | -11.9M | -406.6M | 122.8M | 93.6M | -279.4M | -4.79M | 19.4M |
| Cash from financing | 116.8M | 92.7M | -35.0M | -28.8M | 195.3M | 200.2M | 8.38M | 204.4M | 84.6M | 119.0K |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 1.05M | 1.19M | -419.0K | -284.0K | -2.00K | 1.80M | 1.31M | 847.0K | 556.0K | 179.0K |
| Change in cash | -23.1M | 23.0M | -62.4M | -248.3M | 7.48M | 268.9M | -5.77M | 29.7M | 21.8M | -29.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 16, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 23, 2026 | Material contract | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 17, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Jul 16, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jul 16, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| SC TO-I/A | Jul 6, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| SC TO-I/A | Jul 1, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 4, 2026 | Big-stake notice | SEC |
| SC TO-I | Jun 3, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 3, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 14, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 20, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 10, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 424B5 · Prospectus | Feb 12, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Nov 26, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 26, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jun 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 20, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jun 13, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jun 13, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 19, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 24, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| POSASR | Mar 13, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Dec 9, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 5, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Aug 1, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 29, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 4, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| 424B5 · Prospectus | Mar 8, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| FWP · Free writing prospectus | Mar 7, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Mar 6, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 5, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2024 | Offer document | SEC |
This page holds 200 of 806 filings. Open Filings
Cap table
Built by 6ix from Regenxbio Inc.’s releases · as of Oct 30, 2026
- Common shares
- 66,122,600
- Fully diluted
- 66,122,600
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 66,122,600 | Oct 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$14.92 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 66,122,600 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Argeris N Karabelas Other companies: Bausch Health Companies Inc. (Director · Jun 14, 2016 – Jun 24, 2022 · Past); Rocket Pharmaceuticals, Inc. (Director · Feb 17, 2015 – Jun 24, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Jul 30, 2012 · Past); Vanda Pharmaceuticals Inc. (Director · Apr 12, 2006 – Jun 16, 2011 · Past); Nitromed Inc (Director · Mar 20, 2006 – Apr 24, 2009 · Past) | Director · Since at least Sep 16, 2015 |
| David Stump Other companies: MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Portola Pharmaceuticals Inc (Director · Sep 24, 2015 – Jul 2, 2020 · Past); Dendreon Corp (Director · Jun 2, 2010 – Jan 3, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 18, 2009 – Jun 30, 2020 · Past); Human Genome Sciences Inc (Exec. Vice President · Mar 10, 2009 – Jul 30, 2012 · Past) | Independent Board Member · Since at least Oct 14, 2015 |
| Camille D Samuels Other companies: Unity Biotechnology Inc (Director · May 2, 2018 – Jun 21, 2024 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Oct 1, 2015 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 2, 2011 · Past) | Director · Sep 16, 2015 – Jun 1, 2016 · Past |
| Greg Ciongoli Other companies: Theravance Biopharma, Inc. (Director · Since at least Nov 4, 2026); Gossamer Bio, Inc. (Director · Since at least Sep 16, 2026); Zymeworks Inc. (Director · Since at least Jan 12, 2026); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2025) | Independent Board Member · Since at least Aug 25, 2026 |
| Daniel Tassé Other companies: DBV Technologies SA (Chief Executive Officer · Since at least Jan 1, 2021); Mallinckrodt Inc (Interim Pres-Hospital Business · May 1, 2015 – May 1, 2015 · Past); Bellerophon Therapeutics Inc (Director · Feb 13, 2015 – Jun 21, 2018 · Past) | Independent Board Member · Since at least Aug 15, 2016 |
| Donald J Hayden Jr Other companies: Theseus Pharmaceuticals Inc (Director · May 17, 2022 – Feb 14, 2024 · Past); Amicus Therapeutics Inc (Director · Jan 2, 2018 – Jun 7, 2018 · Past); Insmed Incorporated (Director · Nov 14, 2017 – Apr 9, 2019 · Past) | Director · Oct 11, 2017 – May 29, 2020 · Past |
| Edgar Engleman Other companies: Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Nov 29, 2023 · Past); Soleno Therapeutics, Inc. (Director · Jul 6, 2017 – Feb 5, 2018 · Past); Eiger Biopharmaceuticals Inc (Director · Mar 22, 2016 – Apr 12, 2017 · Past) | Director · Sep 16, 2015 – Sep 22, 2015 · Past |
| Gregory Austin Ciongoli Other companies: Gossamer Bio, Inc. (Director · Since at least Sep 16, 2026); Zymeworks Inc. (Director · Since at least Aug 10, 2025); Atara Biotherapeutics, Inc. (Director · Since at least Sep 3, 2024) | Director · Since at least Aug 25, 2026 |
| Luke Beshar Other companies: Protara Therapeutics, Inc. (Chairman · Since at least Jan 9, 2020); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past) | Director · Sep 16, 2015 – Jun 4, 2021 · Past |
| Daniel J. Abdun-Nabi Other companies: Aptevo Therapeutics Inc. (President · Since at least Aug 1, 2016); Emergent BioSolutions Inc. (CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past) | Director · Aug 5, 2016 – Jun 4, 2021 · Past |
All 29 people
| Person | Seat |
|---|---|
| Mitchell Chan Other companies: Avalo Therapeutics, Inc. (Director · Since at least Dec 1, 2021); Viela Bio Inc (Chief Financial Officer · Oct 2, 2019 – Mar 13, 2021 · Past) | CHIEF FINANCIAL OFFICER · Since at least Sep 16, 2024 |
| Curran M. Simpson Other companies: Human Genome Sciences Inc (Sr. VP, Operations · Mar 10, 2008 – Jul 30, 2012 · Past) | President and Chief Executive Officer, Board Member · Since at least Sep 16, 2015 |
| Faraz Ali Other companies: Tenaya Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 29, 2021) | Chief Business Officer · Feb 29, 2016 – Jan 4, 2017 · Past |
| George Migausky Other companies: Immunovant, Inc. (Director · Dec 1, 2023 – Apr 1, 2025 · Past) | Chairman of the Board · Since at least May 31, 2024 |
| Jean Bennett Other companies: Opus Genetics, Inc. (Director · Since at least Oct 22, 2024) | Director · Since at least Sep 3, 2021 |
| Jennifer Zachary Other companies: Merck & Company, Inc. (EVP, General Counsel · Since at least Apr 16, 2018) | Independent Board Member · Since at least Jun 3, 2022 |
| Steve Pakola Other companies: Whitehawk Therapeutics, Inc. (Chief Medical Officer · Mar 15, 2017 – Feb 15, 2019 · Past) | Chief Medical Officer · Since at least Apr 17, 2019 |
| Alexandra Glucksmann | Independent Board Member · Since at least Jun 3, 2022 |
| Allan Fox | Independent Board Member · Since at least Jun 2, 2026 |
| Allan M Fox | Director · Since at least Sep 16, 2015 |
| Craig Malzahn | Chief Technology Officer · Since at least Mar 13, 2025 |
| Dana Cormack | Corporate Communications · Since at least Nov 3, 2026 |
| Kenneth T Mills | Director · Since at least Sep 16, 2015 |
| Marianne Kreiner | Head of People · Since at least Nov 4, 2026 |
| Olivier Danos | CHIEF SCIENTIFIC OFFICER · Since at least Mar 27, 2017 |
| Patrick J. Christmas | CHIEF LEGAL OFFICER · Since at least Aug 18, 2016 |
| Ram Palanki | Chief Commercial Officer · Since at least Mar 13, 2025 |
| Steve Pakola | CHIEF MEDICAL OFFICER · Since at least Sep 24, 2026 |
| Vittal Vasista | Chief Financial Officer · Sep 16, 2015 – Mar 19, 2024 · Past |
Log in to ask 6ix AI your own questions about Regenxbio Inc.